CYFENDUS

Pre-clinicalRecruiting
0 watching 0 views this week๐Ÿ’ค Quiet
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anthrax

Conditions

Anthrax

Trial Timeline

Nov 1, 2035 โ†’ Nov 1, 2037

About CYFENDUS

CYFENDUS is a pre-clinical stage product being developed by Emergent BioSolutions for Anthrax. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07268612. Target conditions include Anthrax.

Hype Score Breakdown

Clinical
5
Activity
2
Company
2
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT07268612Pre-clinicalRecruiting

Competing Products

15 competing products in Anthrax

See all competitors
ProductCompanyStageHype Score
Cipro (Ciprofloxacin, BAYQ3939)BayerPre-clinical
20
AV7909 Full Dose (0.5 mL) + AV7909 Half Dose (0.25 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)ICON plc.Phase 2
49
AV7909 + BioThraxEmergent BioSolutionsPhase 3
69
AV7909 + BioThraxEmergent BioSolutionsPhase 2
44
AIGIVEmergent BioSolutionsPre-clinical
15
BioThrax + CiprofloxacinEmergent BioSolutionsPhase 2
44
BioThrax + AV7909 Formulation 1 + AV7909 Formulation 2 + AV7909 Formulation 3 + AV7909 Formulation 4 + ControlEmergent BioSolutionsPhase 1
25
Ciprofloxacin 500Mg Tablet + Doxycycline 100Mg Tablet + AV7909Emergent BioSolutionsPhase 2
44
AVP-21D9 + PlaceboEmergent BioSolutionsPhase 1
25
AIGIVEmergent BioSolutionsPre-clinical
15
AIGIV 3.5 mg/kg + Gamunex 90 mg/kg + AIGIV 7.0 mg/kg + Gamunex 180 mg/kg + AIGIV 14.0 mg/kg + Gamunex 360 mg/kgEmergent BioSolutionsPhase 1/2
33
AVA + Ad4-PA-1 + Ad4-PA-GPI-1Emergent BioSolutionsPhase 1
25
BioThraxEmergent BioSolutionsPhase 3
69
RaxibacumabEmergent BioSolutionsPhase 2/3
57
NP-015Emergent BioSolutionsPhase 1
25